Pfizer on Tuesday forecast modest 2026 guidance as it looks to longer-term investments in its pipeline to counter waning Covid product sales and declines from older drugs.Those hurdles aren't surprising or new for Pfizer, which has seen a dramatic decline in Covid vaccine and antiviral sales after raking in record-setting revenue during the pandemic. The drugmaker has pursued deals of all sizes in recent years to build new revenue streams, such as its recently closed $10 billion acquisition of the obesity b ...

Newell Brands will lay off about 10% of its professional and clerical employees, or over 900 workers, as part of its ongoing cost-savings plan. ...

The company said 12,000 of the positions to be cut will be white-collar jobs as it lifts its cost-savings target to $3.77 billion by 2027. ...